Kazazian Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Kazazian Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-6,268	Closed	-$482K	–	98
2018 Q2	$482K	Sell	6,268 -240	-4%	-$15.5K	0.44%	46
2018 Q1	$332K	Hold	6,508	–	–	0.35%	58
2017 Q4	$302K	Sell	6,508 -2,239	-26%	-$110K	0.31%	65
2017 Q3	$466K	Buy	8,747 +5,323	+155%	+$315K	0.57%	40
2017 Q2	$213K	Buy	+3,424	New	+$206K	0.32%	45

Other funds holding RARE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Kazazian Asset Management's RARE Position: Q3 2018 in Review

Kazazian Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2018, closing a stake of 6,268 shares — an estimated $482K sold.

Kazazian Asset Management first reported a position in RARE in Q2 2017 and held it in 5 quarters. The position peaked at $482K in Q2 2018. 177 funds tracked by Wall St. Rank hold RARE as of Q3 2018.

Kazazian Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q3 2018 after selling out during the quarter.
Kazazian Asset Management sold 6,268 Ultragenyx Pharmaceutical shares in Q3 2018, an estimated $482K.
Kazazian Asset Management first reported a position in Ultragenyx Pharmaceutical in Q2 2017 and held it in 5 quarters.
Kazazian Asset Management's Ultragenyx Pharmaceutical position peaked at $482K in Q2 2018.
177 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2018.

Based on Kazazian Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.